HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
E 4021
phosphodiesterase type V inhibitor; structure in first source
Also Known As:
1-(6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl)piperidine-4-carboxylic acid; E-4021; E4021; sodium CMAQP-carboxylate
Networked:
8
relevant articles (
2
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Piperidines: 17
E 4021: 8
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Quinazolines: 402
E 4021: 8
Related Diseases
1.
Pulmonary Hypertension
04/01/1999 - "
We conclude that E4021 may possibly be useful for the treatment of pulmonary hypertension, either alone or in combination with inhaled NO.
"
01/01/1998 - "
We conclude E 4021 may be useful for the treatment of pulmonary hypertension.
"
01/01/1996 - "
A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
"
09/01/1999 - "
We investigated the pulmonary vascular effects of E4021, a potent inhibitor of cGMP-specific phosphodiesterase, in control late-gestation fetal lambs, and in newborn lambs with persistent pulmonary hypertension (PPHN) after prenatal ligation of the ductus arteriosus.
"
01/01/1998 - "
To test whether a potent cGMP-specific phosphodiesterase inhibitor, E 4021, is a selective pulmonary vasodilator in pulmonary hypertension, we studied its acute hemodynamic effects in conscious, chronically hypoxic pulmonary hypertensive rats.
"
2.
Neointima
12/01/1996 - "
In comparison, inhibition of PDE5 alone by E4021 exhibited antiplatelet effects without affecting neointima formation.
"
12/01/1996 - "
twice daily) but not E4021 (3-30 mg/kg, p.o twice daily) inhibited neointima formation in the carotid arteries of spontaneously hypertensive rats (SHRs) subjected to balloon angioplasty.
"
3.
Vascular System Injuries
04/01/1997 - "
In addition, E4021 (9 mg/kg i.v.) and echistatin (250 microg/kg i.v.) caused a similar inhibition of platelet adhesion at sites of microfilament-induced vascular injury in guinea pigs (52% and 65%, respectively).
"
4.
Myocardial Ischemia (Ischemic Heart Diseases)
09/22/1994 - "
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs.
"
09/22/1994 - "
It is concluded that the potent phosphodiesterase type V inhibitor, E4021, administered intravenously or intraduodenally, ameliorated myocardial ischemia similarly to guanylate cyclase activators.
"
5.
Angina Pectoris
09/22/1994 - "
Thus, E4021 may be an orally effective drug in the treatment of angina pectoris.
"
Related Drugs and Biologics
1.
Type 5 Cyclic Nucleotide Phosphodiesterases
2.
Endothelin-1 (Endothelin 1)
3.
Endothelin Receptors (Endothelin Receptor)
4.
Vasodilator Agents (Vasodilators)
5.
Phosphoric Diester Hydrolases (Phosphodiesterases)
6.
Phosphodiesterase Inhibitors
7.
Nitric Oxide (Nitrogen Monoxide)
8.
Guanylate Cyclase (Guanylyl Cyclase)
9.
echistatin
Related Therapies and Procedures
1.
Ligation
2.
Oral Administration